Bluechiip Limited Stock Market Press Releases and Company Profile

View in Other Languages تؤمن Bluechiip Limited ASX:BCT تسجيل FDA وشهادة CE IVD Bluechiip Limited (ASX:BCT) Secures FDA Registration and CE IVD Certification Bluechiip Limited (ASX:BCT) がFDA登録とCE IVD認証を確保 Bluechiip Limited (ASX:BCT) 獲得 FDA 註冊和 CE IVD 認證 Bluechiip Limited (ASX:BCT) 获得 FDA 注册和 CE IVD 认证 Bluechiip Limited (ASX:BCT) obtiene el registro de la FDA y la certificación CE IVD Bluechiip Limited (ASX:BCT) obtient l'enregistrement auprès de la FDA et la certification CE IVD Bluechiip Limited (ASX:BCT) garante o registro da FDA e a certificação CE IVD Bluechiip Limited (ASX:BCT) sichert sich FDA-Registrierung und CE IVD-Zertifizierung Bluechiip Limited(ASX:BCT), FDA 등록 및 CE IVD 인증 확보 Bluechiip Limited (ASX:BCT) Mengamankan Pendaftaran FDA dan Sertifikasi CE IVD Bluechiip Limited (ASX:BCT) ได้รับการรับรองจาก FDA และ CE IVD Certification Bluechiip Limited (ASX:BCT) обеспечивает регистрацию FDA и сертификацию CE IVD 
Bluechiip secures FDA Registration and CE IVD Certification
Bluechiip secures FDA Registration and CE IVD Certification

Melbourne, Nov 30, 2021 AEST (ABN Newswire) - Bluechiip Limited (googlechartASX:BCT) (googlechart1BL:FRA), a leader in the development of advanced sample management solutions for harsh environments, today announced the recent registration of Bluechiip's own branded cryovials with the United States FDA (USA) and receipt of the European CE IVD certification.

These important US and EU certifications enable the company to directly sell into these key target margets.

The company has now globaly launched its Bluechiip-Enabled sample management solutions product line, including Sample Storage consumables, Readers, and Stream(TM) Sample Management Software.

The company plans to market and sell the Bluechiip-Enabled product line directly into North America and Australia/New Zealand and through distribution partners across European and Asia Pacific markets.

Andrew McLellan, Bluechiip Managing Director, described the announcement as very exciting for Bluechiip.

'Certification is important; over the last 18 months we have worked on and achieved certification of our ISO9001 quality management system under which we have validated all our products. FDA registration and CE IVD certification means we can sell directly into the USA, as well as into Europe and the Asia/Pacific region.

The product launch places Bluechiip in a position to directly market a full range of Bluechiip branded products to end customers. We are now talking directly to end customers in biobanking, research, clinical trials, and pharmaceutical companies across the life sciences space. Importantly, we can now deliver customized readers, software and sample storage consumables.

We have also rolled out a marketing campaign, including updating our website. Bluechiip now has a full product catalogue, including a range of accessories, readers and consumables, backed up by appropriate software. We have de-risked the business and are in control of our own future.

Most importantly for our end customers we are focused on redefining quality, driving productivity and at the end of the day providing confidence in every sample and we have already received orders, and made installations, during the past two months in Europe and Australia and look forward to expanding our customer base especially in North America.'

Mr McLellan said Bluechiip was focused on its direct to market products while continuing to work with the company's partners, including FujiFilm Industries Irvine Scientific (FISI), as well as other potential partners to expand Bluechiip's technology application across multiple markets.


About Bluechiip Limited

Bluechiip Ltd ASX BCTBluechiip Ltd (ASX:BCT) understands that every sample - stem cells, blood, eggs, sperm and other biospecimens - is critical, so our objective is to manage each one with optimal quality in the most efficient way. Bluechiip's advanced management solution is the only one that provides sample temperature with ID in cryogenic environments to. Most importantly, this delivers confidence in every sample.

Bluechiip's unique patented technology is a MEMS-based wireless tracking solution that contains no electronics. It represents a generational change from current tracking methods such as labels (hand-written and pre-printed), barcodes (linear and 2D), and Radio Frequency Identification. Bluechiip tags are either embedded or manufactured into storage products such as vials or bags. Each product can be easily identified, and critical information such as sample temperature, is detected by readers and stored in the Bluechiip software. In addition to functioning in extreme temperatures, the Bluechiip(R) Advanced Sample management solution can survive autoclaving, gamma irradiation sterilization, humidification, centrifuging, cryogenic storage and frosting.

Bluechiip's technology has applications in healthcare, including in cryogenic storage facilities (biobanks and biorepositories), pathology, clinical trials and forensics. Other key markets include cold-chain logistics/supply chain, security/defence, industrial/manufacturing and aerospace/aviation.

Bluechiip: Delivering confidence in every sample.

 

https://twitter.com/bluechiip https://www.youtube.com/channel/UCaVcyO4O2oJ_9fLdMs6JIyQ https://www.linkedin.com/company/bluechiip-limited abnnewswire.com 


Contact

Corporate enquiries
Andrew McLellan
Managing Director - CEO
Ph: +61-457-823-470
andrew.mclellan@bluechiip.com

Media
Richard Allen
Ph: +61-3-9915-6341
Oxygen Financial PR
richard@oxygenpr.com.au



ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 19) (Last 30 Days: 54) (Since Published: 4118) 

View in Other Languages 5043411827022557236622322102201419541840178417321654 (32098)

googlechart